Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals Announces Closing of Public Offering of Common Stock

July 18, 2019 • 4:05 PM EDT

Tonix Pharmaceuticals Announces Pricing of Public Offering of Common Stock

July 16, 2019 • 8:30 AM EDT

Tonix Pharmaceuticals Announces Issuance of Patent in China for the Composition and Formulation of TNX-102 SL

June 13, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals Presented Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

May 30, 2019 • 8:00 AM EDT

Tonix Pharmaceuticals to Present at BIO 2019 International Convention

May 28, 2019 • 4:15 PM EDT

Tonix Pharmaceuticals Expands Pipeline with Mid-Stage Biologic Candidate TNX-1300 for Cocaine Intoxication

May 23, 2019 • 7:00 AM EDT

Tonix Pharmaceuticals to Speak at the Second Chance Digital Impact Recipient Gala

May 22, 2019 • 4:19 PM EDT

Tonix Pharmaceuticals Will Present Results from Pharmacokinetic Analyses of TNX-102 SL in a Poster Presentation at the American Society of Clinical Psychopharmacology

May 21, 2019 • 4:15 PM EDT

Tonix Pharmaceuticals Announces Director Stepping Down

May 17, 2019 • 4:05 PM EDT

Tonix Pharmaceuticals Reports First Quarter 2019 Financial Results and Operational Highlights

May 13, 2019 • 8:00 AM EDT

Show All

News / Press Releases : Press Releases